Compare GSK plc (GSK) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Unilever plc — how do they compare? GSK plc trades at $46.46 (market cap $91.88B), while Unilever plc trades at $61.93 (market cap $131.63B). The key difference: Unilever plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Unilever plc for 112 Days on average.
| GSK | UL | |
|---|---|---|
Market Cap | $91.88B | $131.63B |
Volume | 7,730,529 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $74.59 |
52-Week Low | $43.24 | $55.05 |
Typical Hold Time | 93 Days | 112 Days |
Enterprise Value | $111.88B | $156.65B |
Dividend Yield | 3.9% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical outlook and mixed financial performance. Revenue declined to $50.50 billion in 2025, though net income improved to $9.47 billion, with a high net margin of 18.74%. Recent earnings have consistently missed expectations, while the company is streamlining its portfolio through a planned food business merger with McCormick, facing regulatory scrutiny.
The stock presents a cautious outlook with strong profitability metrics like a 54.56% ROE offset by valuation concerns (P/E of 21.59) and earnings misses. Risks include integration challenges from the McCormick deal and competitive pressures, but its focus on beauty and personal care offers growth potential in emerging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
